November 28, 2018

US Bioservices now dispenses VITRAKVI

US Bioservices, a specialty pharmacy that is a part of AmerisourceBergen, today announced that it has been selected by Bayer and its collaboration partner Loxo Oncology, Inc. to dispense Vitrakvi® (larotrectinib). Vitrakvi was approved by the U.S. Food and Drug Administration (FDA) on November 26, 2018. Vitrakvi is an oral tropomyosin receptor kinase (TRK) inhibitor for the treatment of adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have no satisfactory alternative treatments or that have progressed following treatment.